Nasal drug delivery has evolved into a versatile route for both new and reformulated therapies, from intranasal vaccination to emerging nose-to-brain delivery.
But as the opportunities for nasal drug delivery grow, so too does the complexity. Every nasal product is unique, and developers must navigate formulation and device challenges, such as mucosal clearance and bioavailability, whilst meeting stringent manufacturing and regulatory demands.
In our latest article with International Pharmaceutical Industry Journal, Bespak’s Director of Business Development, Joseph DePalo, explores how specialist CDMOs can offer the expertise, technology and facilities to help scale nasal drug-device combination products to the clinic and beyond.
Read the full article here.
